Lenvatinib (mesylate) (Standard)

Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate) . This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

Product Specifications

CAS Number

[857890-39-2]

Product Name Alternative

E7080 (mesylate) (Standard)

UNSPSC

12352005

Hazard Statement

H361-H373

Target

C-Kit; FGFR; PDGFR; Reference Standards; RET; VEGFR

Type

Reference Standards

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lenvatinib-mesylate-standard.html

Smiles

O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O

Molecular Formula

C22H23ClN4O7S

Molecular Weight

522.96

Precautions

P260-P280-P405-P501

References & Citations

[1]Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391 (10126) :1163-1173.|[2]Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25 (1) :1073274818789361.|[3]3.Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14 (17),545.|[4]Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122 (3), 664-671.